What Damora Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 1 | 1 |
| Sells | 0 | 4 |
| Total trades | 1 | 15 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 418,974,535 |
| Disposed | 0 | 49,295 |
| Net activity | +0 | +418,925,240 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | Sep 25 | Open-market buy · P | +12,500 | $20.23 | +$253K | 512,500 |
| Winslow Garrett | General Counsel | Jul 06 | Open-market sale · S | −245 | $29.98 | −$7.35K | 2,289 |
| Winslow Garrett | General Counsel | Jul 03 | Exercise / conversion · M | +680 | — | — | 2,534 |
| Jarrett Jennifer | See Remarks | Mar 30 | Grant / award · A | +500,000 | — | — | 500,000 |
| Bruno Julianne | Director | Feb 09 | Exercise / conversion · M | +129,000 | — | — | 137,032 |
| Fairmount Funds Management Llc | Director | Feb 09 | Exercise / conversion · M | +2,904,000 | — | — | 2,904,000 |
| Fairmount Funds Management Llc | Director | Feb 09 | Exercise / conversion · M | +5,809,000 | — | — | 5,809,000 |
| Hewes L. Becker | Chief Medical Officer | Jan 05 | Grant / award · A | +264,629 | — | — | 264,629 |
| Sattarzadeh Sherwin | Chief Operating Officer | Jan 05 | Grant / award · A | +190,376 | — | — | 190,376 |
| Schambye Hans T. | Chief Executive Officer | Jan 02 | Open-market sale · S | −700 | $21.38 | −$15K | 4,682 |
| Schambye Hans T. | Chief Executive Officer | Jan 02 | Exercise / conversion · M | +1,360 | — | — | 5,382 |
| Firmani Lori | Chief Financial Officer | Jan 02 | Open-market sale · S | −135 | $21.41 | −$2.89K | 931 |
| Firmani Lori | Chief Financial Officer | Jan 02 | Exercise / conversion · M | +374 | — | — | 1,066 |
| Winslow Garrett | General Counsel | Jan 02 | Open-market sale · S | −255 | $21.38 | −$5.45K | 1,854 |
| Winslow Garrett | General Counsel | Jan 02 | Exercise / conversion · M | +680 | — | — | 2,109 |
| Schambye Hans T. | Chief Executive Officer | Jul 03 | Open-market sale · S | −735 | $3.38 | −$2.48K | 4,022 |
| Schambye Hans T. | Chief Executive Officer | Jul 03 | Exercise / conversion · M | +1,360 | — | — | 4,757 |
| Firmani Lori | Interim CFO | Jul 03 | Open-market sale · S | −147 | $3.39 | −$498 | 692 |
| Firmani Lori | Interim CFO | Jul 03 | Exercise / conversion · M | +374 | — | — | 839 |
| Winslow Garrett | General Counsel | Jul 03 | Open-market sale · S | −260 | $3.39 | −$881 | 1,429 |
Loading...
